STOCK TITAN
  1. Home
  2. News
  3. JNJ

Johnson & Johnson - $JNJ STOCK NEWS

Welcome to our dedicated page for Johnson & Johnson news (Ticker: $JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Johnson & Johnson's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Johnson & Johnson's position in the market.

News
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Rhea-AI Summary
Johnson & Johnson (JNJ) receives FDA approval for CARVYKTI® for the treatment of relapsed or refractory multiple myeloma, offering patients a potential treatment-free period as early as first relapse. The approval is based on positive results from the Phase 3 CARTITUDE-4 study, showing a 59% reduction in the risk of disease progression or death compared to standard therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
News
Johnson & Johnson to Acquire Shockwave Medical
Rhea-AI Summary
Johnson & Johnson (JNJ) to acquire Shockwave Medical, Inc. (SWAV) for $13.1 billion, enhancing its position in cardiovascular intervention. The acquisition aims to drive sales growth, improve patient outcomes, and accelerate operating margin. Shockwave's IVL technology for calcified CAD and PAD treatment aligns with JNJ's focus on cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
acquisition
-
News
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Rhea-AI Summary
Johnson & Johnson (JNJ) received an unsolicited mini-tender offer from TRC Capital Investment to purchase up to 1 million shares at $151.23 per share, 4.12% lower than the previous closing price. JNJ advises shareholders not to tender their shares due to the offer being below market price and subject to conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
News
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the BofA Securities Health Care Conference with John Reed representing the company. The live audio webcast will be available for investors on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
News
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Rhea-AI Summary
Johnson & Johnson (JNJ) will host a conference call to review first-quarter results, featuring top executives. Investors can access the webcast and presentation material on the company's website. The press release provides details on accessing the call and future earnings calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
News
Johnson & Johnson Completes Acquisition of Ambrx
Rhea-AI Summary
Johnson & Johnson (JNJ) completes the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion, strengthening its commitment to innovation in prostate cancer. The acquisition deepens JNJ's pipeline of next-generation antibody drug conjugates (ADCs) and targeted oncologic therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
acquisition
News
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Rhea-AI Summary
Johnson & Johnson's RYBREVANT® Receives FDA Approval for First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations, Showing 61% Reduction in Disease Progression or Death in Phase 3 PAPILLON Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
fda approval
-
News
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Rhea-AI Summary
Johnson & Johnson's TECVAYLI® receives FDA approval for biweekly dosing, offering flexibility to patients with relapsed or refractory multiple myeloma. The bispecific antibody targets BCMA and CD3, activating an immune response. The approval is based on the Phase 1/2 MajesTEC-1 study results, allowing reduced dosing frequency for patients achieving a complete response for six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
Rhea-AI Summary
Johnson & Johnson (JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference. Peter Menziuso will represent the Company in a session on March 13th, at 10:45 a.m. (Eastern Time) at the Loews Miami Beach Hotel. Investors can access the live audio webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
conferences
News
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
Rhea-AI Summary
Johnson & Johnson (JNJ) to participate in Leerink Global Biopharma Conference with Joe Wolk, EVP, CFO representing the company. The live webcast will be available on their website for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences
Stock JNJ logo
Johnson & Johnson

NYSE:JNJ

JNJ Rankings

#21 Ranked by Market Cap
#3104 Ranked by Stock Gains
#1052 Ranked by Dividends

JNJ Stock Data

372.17B
2.40B
0.09%
71.24%
0.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW BRUNSWICK

About JNJ

Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.